Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability

Core Viewpoint - Exagen (NASDAQ: XGN) is initiated with a Buy rating, indicating a positive outlook on the company's performance and growth potential [1] Company Performance - Exagen's turnaround is gaining traction, suggesting improvements in operational efficiency and market positioning [1] - The core AVISE diagnostics franchise is experiencing growth, which is a key driver for the company's revenue [1] - Margins are improving, indicating better cost management and profitability [1] Product Development - The company has recently added new biomarker tests for lupus and rheumatoid arthritis (RA), expanding its product offerings and addressing additional market needs [1]